<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sacrococcygeal teratoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sacrococcygeal teratoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sacrococcygeal teratoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rachel A Egler, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah Levine, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynn L Simpson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Germ cell tumors (GCTs) that arise outside the testes or the ovaries are classified as extragonadal. Extragonadal GCTs typically arise in midline locations, and specific sites vary with age. In adults, the most common sites are the anterior mediastinum, retroperitoneum, and the pineal and suprasellar regions. In infants and young children, sacrococcygeal teratomas (SCTs) are the most common GCTs.</p><p>SCTs are discussed here. Extragonadal GCTs arising in the central nervous system and in the mediastinum and retroperitoneum are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/5199.html" rel="external">"Intracranial germ cell tumors"</a> and  <a class="medical medical_review" href="/d/html/2998.html" rel="external">"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>SCT is the most common germ cell tumor (GCT) of childhood. In the pediatric population, SCTs account for 40 percent of all GCTs and up to 78 percent of all extragonadal GCTs. Rarely, SCTs may present in adulthood [<a href="#rid1">1,2</a>].</p><p>SCT is the most frequently recognized fetal neoplasm, with an estimated incidence of approximately 1 in 27,000 [<a href="#rid3">3</a>]. SCTs are more common in females than males, with a 3 to 4:1 ratio [<a href="#rid4">4,5</a>]. SCTs with malignant elements generally are not seen in infants. The incidence of malignant elements within SCTs increases with postnatal age.</p><p class="headingAnchor" id="H3"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H4"><span class="h2">Histology</span><span class="headingEndMark"> — </span>Teratomas often are comprised of cells that represent all three germ cell layers. They have solid, cystic, or mixed components. Unlike teratomas in other locations, SCTs often do not have a capsule or pseudocapsule, which contributes to the difficulty in achieving a complete resection.</p><p>As teratomas, SCTs can include mature, immature, and malignant tissues:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mature teratomas</strong> – Mature teratomas consist of fully differentiated tissues from various somatic sites. These tissues may be small islands of cells mixed together, or they can include fully functional glandular structures such as pancreatic Langerhans cells or sebaceous glands. Fully developed bone, hair, and teeth have been found in mature teratomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immature teratomas</strong> – Immature teratomas include at least a small fraction of cells that are comprised of embryonal components or incompletely differentiated tissue structures. Primitive neuroectodermal features, such as primitive neural tubes and immature rosettes, are common. The Gonzalez-Crussi grading system has been used to describe the amount of immature tissue within the tumor: Grade 0: mature teratoma only; Grade 1: &lt;10 percent immature tissue; Grade 2: 10 to 50 percent immature tissue; and Grade 3: &gt;50 percent immature tissue [<a href="#rid6">6</a>]. Other grading systems have also been described [<a href="#rid7">7-9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant teratomas</strong> – SCTs that contain any malignant elements are considered malignant. Between 11 and 35 percent of postnatal SCTs are malignant, and many of these will have elevated tumor markers [<a href="#rid4">4,10,11</a>]. The most common malignant element is a yolk sac component, which produces alpha-fetoprotein (AFP) [<a href="#rid4">4,9,12</a>]. Other malignant elements can include embryonal carcinoma and primitive neuroectodermal tumor (PNET).</p><p></p><p>Microfoci of malignant elements can be missed on pathologic sectioning. Therefore, screening with AFP and beta human chorionic gonadotropin (beta-hCG) is part of the initial evaluation of patients with SCT. (See <a class="local">'Prenatal detection'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>No consistent genetic changes have been identified in mature and immature teratomas [<a href="#rid6">6</a>]. Both gonadal and extragonadal germ cell tumors (GCTs) of infancy frequently have gain of chromosomes 1q and 20q, as well as loss of chromosomes 1p and 6q. By contrast, postpubertal malignant GCTs are associated with the isochromosome 12p abnormality [<a href="#rid6">6,13,14</a>]. (See  <a class="medical medical_review" href="/d/html/2998.html" rel="external">"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>SCT generally presents either in utero, as a mass extending off the caudal end of the fetus, or as a tumor of infancy that may be asymptomatic or present with signs of obstruction of the rectum or bladder [<a href="#rid15">15,16</a>]. A small number of children present with weakness, pain, or paralysis [<a href="#rid17">17</a>].</p><p>The Altman Classification describes the extent to which a tumor is external and/or internal  (<a class="graphic graphic_figure graphicRef81430" href="/d/graphic/81430.html" rel="external">figure 1</a>). Type I tumors are primarily external, while type IV lesions are completely internal. Type I and II tumors are the most obvious on prenatal ultrasound and clinical examination. In the United Kingdom Children's Cancer Study Group (UKCCSG) experience with 37 SCTs, Altman types I, II, III, and IV were present in 62, 14, 19, and 6 percent of cases, respectively [<a href="#rid7">7</a>].</p><p>Type IV tumors typically are found later in infancy and early childhood, compared with tumors with an external component (types I, II, and III). Type IV SCTs can present with obstipation/constipation, abdominal pain, or a palpable mass. Malignant elements are more frequent in type IV SCTs, with an incidence of 38 percent in one series [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H7"><span class="h1">PRENATAL DETECTION</span><span class="headingEndMark"> — </span>Prenatal diagnosis typically occurs during the second trimester during routine sonography; first-trimester diagnosis has also been reported [<a href="#rid19">19-22</a>]. Most SCTs diagnosed in utero are Altman type I or II [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H5386466"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Sonography usually demonstrates a mass near the distal spine  (<a class="graphic graphic_picture graphicRef88674" href="/d/graphic/88674.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef88673" href="/d/graphic/88673.html" rel="external">picture 2</a>). The majority of prenatally diagnosed SCTs are either solid or mixed cystic and solid; calcifications are often present. Associated structural abnormalities may include bladder outlet obstruction and hydronephrosis, rectal stenosis or atresia, and cardiomegaly secondary to vascular shunting and high-output cardiac failure. (See <a class="local">'Evaluation and monitoring'</a> below.)</p><p>Fetal magnetic resonance imaging (MRI) is recommended where available. Compared with sonography, MRI more accurately characterizes the intrapelvic and abdominal extent of the tumor and compression of adjacent organs  (<a class="graphic graphic_picture graphicRef88675" href="/d/graphic/88675.html" rel="external">picture 3</a>) [<a href="#rid23">23-25</a>]. This information can help in prenatal counseling and preoperative planning for surgical resection. (See <a class="local">'Perinatal management'</a> below.)</p><p>The most important differential diagnosis of an exophytic cystic sacral mass in the fetus is a distal neural tube defect (myelomeningocele or myelocystocele) [<a href="#rid19">19,26-28</a>]. A neural tube defect is diagnosed when the spinal elements are splayed posteriorly and there is a meningocele or meningomyelocele. SCTs always have a portion in close proximity to the coccyx; they may impinge on the sacrum, but the mass effect is usually presacral rather than posterior, as a neural tube defect would be. Both entities can be associated with elevated maternal and amniotic alpha-fetoprotein (AFP) levels. MRI can be helpful when the diagnosis is unclear by ultrasound [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H24780332"><span class="h2">Evaluation and monitoring</span><span class="headingEndMark"> — </span>Serial ultrasound evaluation of the fetus, placenta, and tumor over the course of the gestation is an important component in the overall treatment plan. The major goal is to identify fetuses at increased risk of fetal demise because of hydrops (ie, high-output cardiac failure due to the vascularity and size of the mass) and intervene as appropriate. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis"</a>.)</p><p>Tumor size should be measured at each ultrasound examination, and solid portions of the tumor should be interrogated with Doppler ultrasound to assess vascular flow. Rapidly enlarging tumors and tumors that are solid, in particular, create a vascular steal phenomenon, which places the fetus at increased risk of developing hydropic changes [<a href="#rid29">29,30</a>]. Large lesions (&gt;10 cm), especially vascular ones, are associated with a high perinatal mortality rate. Relatively cystic lesions with absent or mild vascularity tend to display slow growth and have a favorable outcome, even when large (&gt;10 cm) [<a href="#rid31">31</a>]. Amniotic fluid volume and placental thickness should also be evaluated, as polyhydramnios and placental thickening are markers for hydrops, and oligohydramnios can result from bladder obstruction due to the SCT.</p><p>The frequency of ultrasound examinations depends on the composition of the tumor (ie, cystic or solid), its vascularity, and any associated findings; follow-up imaging may be as often as twice per week for high-risk tumors, or as infrequently as every two weeks for small or predominantly cystic lesions.</p><p>Fetal echocardiography is recommended in fetuses with predominantly solid and/or vascular tumors. Echocardiography is used to identify a high-output cardiac state, which precedes the onset of hydrops [<a href="#rid32">32</a>]. A fetal cardiac profile consisting of assessment of the cardiothoracic ratio, cardiac dimension z scores, combined ventricular output, and valvular regurgitation can be used to identify fetuses with poor prognosis [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H91044340"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Imaging characteristics, particularly tumor volume, may provide prognostic information [<a href="#rid30">30,34-36</a>]. For example, tumor-volume-to-fetal-weight ratio (TFR) &gt;0.12 on ultrasound before 24 weeks of gestation is a poor prognostic sign [<a href="#rid15">15,30,34,35,37</a>]. In a single-center retrospective study, TFR &gt;0.12 on ultrasound before 24 weeks of gestation was associated with 4.7-fold increase in risk of poor prognosis (hydrops, perinatal death, need for fetal intervention), and a TFR ≥0.11 before 32 weeks was associated with a 6.2-fold increase [<a href="#rid35">35</a>]. In another study, a solid-tumor-volume-to-head-volume ratio &gt;1 was associated with a perinatal mortality rate of 61 percent due to high-output failure and hydrops [<a href="#rid30">30</a>].</p><p>A 2023 meta-analysis of 12 studies comprising 447 prenatally diagnosed SCT cases provided information on characteristics associated with a poor outcome (defined as pregnancy termination, fetal death, or neonatal death) [<a href="#rid38">38</a>]. Approximately one-third of cases had a poor outcome; of these, approximately 12 percent were pregnancy terminations, 7 percent were fetal deaths, and 13 percent were neonatal deaths. The frequency of poor outcome with versus without the characteristic was as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Solid tumor morphology (69 versus 11 percent; OR 20.0, 95% CI 7.9-50.4)</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal hydrops (66 versus 18 percent; OR 9.4, 95% CI 4.0-22.1)</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiomegaly (60 versus 13 percent; OR 7.3, 95% CI 1.9-28.3)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypervascular tumor (55 versus 13 percent; OR 6.2, 95% CI 2.3-16.8)</p><p class="bulletIndent1"><span class="glyph">●</span>Placentomegaly (76 versus 43 percent; OR 4.1, 95% CI 1.6-10.4)</p><p></p><p>Tumor volume to fetal weight ratio (TFR) &gt;0.12 before 24 weeks of gestation was also predictive of a poor outcome (sensitivity 92 to 100 percent, specificity 76 to 83 percent). Altman type I/II versus type III/IV was not a statistically significant risk factor for poor outcome (24 versus 17 percent; OR 1.3, 95% CI 0.4-4.6).</p><p>Other findings included that the mean gestational age at birth in ongoing pregnancies was 32.5 weeks and that perinatal death was mostly due to tumor hemorrhage with hemodynamic failure. The relationship between mode of delivery and outcome was not analyzed, but most live births were by planned cesarean.</p><p>A systematic review of 18 studies comprising 420 pregnancies complicated by SCT published in 2015 reported additional findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Survival by Altman type: Type I (78 percent), Type II (70 percent), Type III (86 percent), Type IV (80 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fifty-two percent of survivors were delivered at &lt;34 weeks of gestation</p><p></p><p class="headingAnchor" id="H20606441"><span class="h2">Perinatal management</span><span class="headingEndMark"> — </span>Prenatal diagnosis and close monitoring have improved outcomes for fetal SCT, but overall perinatal mortality remains high [<a href="#rid39">39</a>]. Estimates of perinatal mortality for prenatally diagnosed SCT range from 25 to 50 percent when cases of pregnancy termination, intrauterine death, and neonatal death are included [<a href="#rid19">19,40</a>]. Potential perinatal complications include preterm labor, spontaneous tumor hemorrhage or rupture [<a href="#rid41">41</a>], and maternal Mirror syndrome (maternal edema and hypertension mirroring fetal hydrops). (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Mirror syndrome'</a>.)</p><p>In utero interventions are generally only temporizing measures to decrease the impact of the parasitic mass on the fetal cardiovascular system, allowing the fetus to recover in utero and continue to grow and mature. A definitive surgical procedure is typically required after the child's birth. For some high-risk SCT fetuses, in utero open fetal surgery is an option at specialized centers. Although criteria for open fetal surgery vary across centers, most include fetuses with high-risk SCT and hydrops developing at a gestational age earlier than appropriate for delivery and neonatal care (eg, 28 to 32 weeks gestation). Contraindications to open fetal surgery include type III or IV Altman-type tumors, severe placentomegaly, cervical shortening, and maternal medical issues [<a href="#rid39">39</a>]. Minimally invasive in utero approaches for management of the hydropic fetus with SCT include laser ablation [<a href="#rid42">42,43</a>], radiofrequency ablation [<a href="#rid44">44,45</a>], bladder drainage for obstructive uropathy [<a href="#rid19">19,46</a>], and cyst aspiration [<a href="#rid47">47</a>]. In a 2014 systematic review, overall perinatal survival with open fetal surgery was 50 percent (6 out of 12) [<a href="#rid48">48</a>]. For minimally invasive procedures, overall perinatal survival was 44 percent (14 out of 32); 30 percent of hydropic fetuses survived (6 out of 20) and 67 percent (8 out of 12) of fetuses without obvious hydrops survived. Mean gestational age at birth for the entire cohort was 30 weeks. Minimally invasive procedures resulting in tumor necrosis enabled performance of a lower-segment uterine incision rather than a classical incision during cesarean delivery.</p><p>In high-risk SCT fetuses that are not candidates for in utero intervention, the third trimester can be unpredictable, even with close monitoring. In selected high-risk SCT fetuses, early delivery and ex utero surgery are an option, as advocated by investigators at the Center for Fetal Diagnosis and Treatment at Children's Hospital of Philadelphia [<a href="#rid39">39</a>]. They suggest cesarean delivery, using an ex utero intrapartum therapy (EXIT) procedure when possible, for high-risk SCT after 27 to 28 weeks. High-risk SCTs are those with fetal high-output cardiac failure, tumor hemorrhage, nonreassuring fetal testing (biophysical profile, fetal heart rate tracing, abnormal Dopplers), or impending preterm labor due to polyhydramnios and/or tumor size. In EXIT, the fetus is partially delivered and intubated without clamping the umbilical cord; uteroplacental blood flow and gas exchange are maintained by using inhalational agents to provide uterine relaxation and amnioinfusion to maintain uterine volume. This provides time for debulking the SCT prior to complete delivery of the infant, thereby interrupting the vascular steal that is the basis for high-output cardiac failure.</p><p>Fetuses with low-risk SCT are typically delivered by cesarean after 36 weeks of gestation [<a href="#rid39">39</a>]. Fetuses with small tumors (&lt;5 cm) can be delivered vaginally, but the majority of tumors are sufficiently large to necessitate cesarean delivery [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H20606448"><span class="h1">POSTNATAL EVALUATION</span><span class="headingEndMark"> — </span>If fetal MRI was not performed antenatally, computed tomography (CT) or MRI of the primary site is commonly done after birth to assess the extent of internal tumor. Staging should include a CT of the chest and bone scan.</p><p>Serum levels of alpha-fetoprotein (AFP) and beta human chorionic gonadotropin (beta-hCG) should be assessed at diagnosis to look for the presence of malignant components in the tumor. Because these tumors generally present at birth or early in infancy, interpretation of an elevated AFP can be difficult and must consider the age of the patient [<a href="#rid50">50</a>]. AFP levels often decline slowly to reach normal levels in the very young, but a continued decline should be present [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H530304869"><span class="h1">SURGICAL RESECTION</span><span class="headingEndMark"> — </span>In most cases, surgical resection is undertaken postnatally. In utero interventions are generally only temporizing measures, allowing the fetus to recover in utero and continue to grow and mature; in selected cases at specialized centers, resection may be undertaken in utero. (See <a class="local">'Perinatal management'</a> above.)</p><p>For tumors deemed resectable at diagnosis, maximal safe resection is recommended. Surgery for complete excision of an SCT often is quite extensive. It must include removal of the coccyx to be considered complete. Other considerations include early ligation of the sacral vessels and sterile circumferential preparation of the body due to the potential need for intraoperative change in approach [<a href="#rid52">52</a>]. If a complete resection cannot be achieved in the first surgery, a second procedure may be required to complete the resection, particularly for tumors with malignant elements [<a href="#rid10">10,53</a>].</p><p>Despite successful control of the tumor in the majority of patients, functional sequelae are common and can impair quality of life [<a href="#rid54">54,55</a>]. The frequency of serious complications was assessed in a series of 79 patients from the Netherlands who were treated from 1980 to 2003 [<a href="#rid54">54</a>]. Bowel dysfunction (soiling, including total fecal incontinence in some cases) was reported in 13 percent and urinary incontinence was observed in 31 percent. In a more recent series of 45 patients treated from 2000 to 2013 in the United States, anorectal complications occurred in 29 percent and urologic complications occurred in 33 percent [<a href="#rid56">56</a>]. No anorectal or urologic complications occurred in patients with Altman type I tumors.</p><p class="headingAnchor" id="H8"><span class="h1">POSTOPERATIVE THERAPY</span></p><p class="headingAnchor" id="H9"><span class="h2">Benign SCT</span><span class="headingEndMark"> — </span>The majority of SCTs do not contain malignant elements. Early, complete surgical resection is the cornerstone of management for mature and immature SCTs in this setting [<a href="#rid2">2,8,9,12,18,57,58</a>]. Surgical resection is often an extensive procedure and can cause significant acute and long-term side effects. (See <a class="local">'Surgical resection'</a> above.)</p><p>Incomplete resections are associated with a significantly higher rate of recurrence. In a German series, recurrence was more frequent after incomplete resection (49 versus 11 percent, in those with complete resection) [<a href="#rid12">12</a>]. Similarly, the Children's Cancer Group (CCG) observed a recurrence rate of 11 percent in patients with mature SCT [<a href="#rid4">4</a>]. Of these, two recurrences were mature teratoma, while the remaining seven had yolk sac tumors [<a href="#rid4">4</a>].</p><p>Both German and United Kingdom investigators found no benefit for adjuvant chemotherapy in patients with immature teratoma [<a href="#rid8">8,12</a>]. Similarly, the American Intergroup study demonstrated that observation after complete resection was an effective strategy in patients with immature teratoma [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H10"><span class="h2">SCT with malignant elements</span><span class="headingEndMark"> — </span>SCTs with malignant elements are staged postoperatively following Children's Oncology Group (COG) staging guidelines for extragonadal germ cell tumors (GCTs)  (<a class="graphic graphic_table graphicRef139047" href="/d/graphic/139047.html" rel="external">table 1</a>). Stage I refers to completely resected tumors with negative pathologic margins and no evidence of lymph node involvement. Stage II includes resected tumors with microscopic residual disease but negative lymph nodes. Stage III includes patients with gross residual/unresectable tumor or positive lymph nodes, and stage IV refers to patients with distant metastases.</p><p>The natural history and prognosis of malignant SCTs vary by stage and inform the treatment approach. Stage I and II malignant SCTs treated with complete surgical resection and chemotherapy have an overall survival (OS) at five years that exceeds 90 percent [<a href="#rid10">10,59,60</a>]. Metastatic tumors have a lower event-free survival (EFS) and OS. In a combined analysis of three German trials that utilized surgery followed by a five-drug chemotherapy regimen, outcomes were worse for those with metastatic tumors (five-year EFS 67 versus 83 percent in those without metastases, and OS 69 versus 92 percent) [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I</strong> – For stage I SCTs with malignant elements, the treatment approach has evolved, and many pediatric oncologists prefer a watch-and-wait strategy rather than proceeding immediately with adjuvant chemotherapy. These patients are often infants, and a period of watch-and-wait postpones and sometimes avoids the toxicities of chemotherapy while the child has time to grow and mature.</p><p></p><p class="bulletIndent1">Limited observation data suggest that this is a reasonable strategy. A case series and review of the literature identified 14 cases of stage I SCT with malignant components, 12 of whom survived with no recurrence at last follow-up, ranging from two to eight years [<a href="#rid61">61</a>]. Two patients who recurred were treated with platinum-based chemotherapy and were alive at nine years.</p><p></p><p class="bulletIndent1">The shift towards observation for stage I SCTs with malignant elements is reflected in cooperative group trial design. In the actively enrolling COG trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03067181&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiSEzpcEAR1SgfL42gunkUEYKTA7MnfeSeaHV3BNzyhywA%3D%3D&amp;TOPIC_ID=5200" target="_blank">AGCT 1531</a>), stage I extragonadal GCTs such as SCT are observed without immediate chemotherapy, whereas in the last completed trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT00053352&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSyK1EnvHn%2FgiqApVXxtC3NgGEmt77b2fkjF7Nw7GP3VMQ%3D%3D&amp;TOPIC_ID=5200" target="_blank">AGCT 0132</a>), patients with a completely resected malignant SCT were considered to have intermediate-risk disease and received at least three cycles of BEP (<a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>) therapy [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II</strong> – For stage II SCTs with malignant elements, adjuvant chemotherapy remains the standard of care, using a platinum-based multidrug regimen such as such as BEP or BEJ (<a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>) [<a href="#rid59">59,60,62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stages III and IV</strong> – For patients with advanced disease, neoadjuvant chemotherapy has been used prior to an attempt at complete resection [<a href="#rid12">12,53,59</a>]. In patients with locally advanced or metastatic disease, those who received neoadjuvant chemotherapy followed by resection had an EFS of 79 percent with an OS of 83 percent at five years, while those who had an immediate attempt at complete resection had both EFS and OS of 49 percent [<a href="#rid12">12</a>]. The American Intergroup data showed similar results, with all nonthoracic, extragonadal GCTs having an EFS and OS of 82 and 87 percent, respectively, at five years [<a href="#rid53">53</a>]. In the United Kingdom Children's Cancer Study Group (UKCCSG) experience, patients with malignant sacrococcygeal GCT who were treated with neoadjuvant chemotherapy with BEJ had an EFS of 87 percent [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h1">SURVEILLANCE AND RELAPSE</span><span class="headingEndMark"> — </span>Children require regular follow-up after surgical resection or completion of chemotherapy. Surveillance guidance is based on expert opinion and clinical experience and typically involves clinical examination at three- to six-month intervals, with monthly tumor marker measurement (alpha-fetoprotein [AFP]) and lactate dehydrogenase (LDH) for the first year and then every two to six months. Primary site imaging (usually MRI) and chest radiograph are obtained at 3 and 12 months after resection and then as needed for evaluation of new symptoms. Follow-up should continue for at least three to five years, as late recurrences have been reported [<a href="#rid4">4,63</a>].</p><p>As discussed above (see <a class="local">'Postnatal evaluation'</a> above), interpretation of an elevated AFP after surgical resection can be difficult in infants and must consider the age of the patient [<a href="#rid50">50</a>]. AFP levels often decline slowly after birth and can take months to reach normal levels, but a continued decline should be present [<a href="#rid50">50,51,64,65</a>].</p><p>Approximately three-quarters of children with recurrent SCT will have an elevated AFP, including some who had mature teratoma initially [<a href="#rid66">66</a>]. Most recurrences are detected through physical examination or high AFP levels; others may be diagnosed by MRI, CT, or ultrasound after symptoms such as constipation are reported [<a href="#rid63">63</a>].</p><p>Both mature and immature teratomas can recur locally and at distant sites, and recurrence is associated with decreased overall survival (OS) [<a href="#rid9">9,12</a>]. The overall recurrence rate is approximately 10 percent for mature teratomas and approximately 20 percent for immature teratomas. The vast majority of patients with distant relapse also have recurrent locoregional disease [<a href="#rid12">12</a>]. In addition to immature or malignant histology, risk factors for recurrence include incomplete resection and tumor spillage at the time of surgery [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H1489978006"><span class="h1">TREATMENT OF RECURRENCE</span><span class="headingEndMark"> — </span>Patients with recurrent disease are treated with further surgery or chemotherapy depending upon the pathology and extent of the recurrent tumor. SCT patients who recur with malignant elements can often be salvaged with platinum-based therapy [<a href="#rid8">8,9,12</a>]. (See <a class="local">'SCT with malignant elements'</a> above.)</p><p>Patients previously treated with chemotherapy (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [BEP] or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> [JEB]) for malignant disease can be treated with a number of salvage regimens for recurrent malignant germ cell tumor (GCT) including <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, and cisplatin [<a href="#rid68">68</a>]; <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, ifosfamide, and platinum [<a href="#rid69">69</a>]; and high-dose chemotherapy with stem cell rescue [<a href="#rid55">55,70-72</a>]. The most recent Children's Oncology Group (COG) study for refractory GCTs used a combination of paclitaxel, ifosfamide, and carboplatin [<a href="#rid73">73</a>]. The study showed a good response rate in typical, younger patients with SCT, but this combination did not appear superior to other regimens used in the adolescent and young adult population.</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Sacrococcygeal teratoma (SCT) is the most common germ cell tumor (GCT) in infancy and early childhood  (<a class="graphic graphic_figure graphicRef81430" href="/d/graphic/81430.html" rel="external">figure 1</a>). SCTs are generally benign tumors. However, malignant elements can be present, and their frequency increases with the postnatal age of the patient. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prenatal detection and monitoring</strong> – As most SCTs are identified during pregnancy, serial ultrasound evaluation of the fetus, placenta, and tumor over the course of the gestation is an important component in the overall treatment plan  (<a class="graphic graphic_picture graphicRef88673" href="/d/graphic/88673.html" rel="external">picture 2</a>). The major goal is to identify fetuses at increased risk of fetal demise because of hydrops (ie, abnormal fetal fluid collections), and intervene as appropriate. (See <a class="local">'Evaluation and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perinatal management</strong> – In most cases, surgical resection is undertaken postnatally. In utero interventions are generally only temporizing measures, allowing the fetus to recover in utero and continue to grow and mature; in very selected cases at specialized centers, resection may be undertaken in utero. (See <a class="local">'Perinatal management'</a> above and <a class="local">'Surgical resection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postnatal management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benign SCT</strong> – For benign (mature and immature) SCTs, early, complete surgical resection is the cornerstone of management. There does not appear to be a role for adjuvant chemotherapy following surgery. (See <a class="local">'Benign SCT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SCT with malignant elements, stage I or II</strong> – For tumors deemed resectable at diagnosis, maximal safe resection should be undertaken. Postoperatively, the approach depends on staging  (<a class="graphic graphic_table graphicRef139047" href="/d/graphic/139047.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2">For most patients with stage I disease (complete resection, negative pathologic margins), we suggest observation rather than immediate chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with stage II disease (microscopic residual, negative lymph nodes), adjuvant chemotherapy remains the standard of care. We suggest a platinum-based regimen such as <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (BEP) or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> (BEJ), rather than alternative chemotherapeutic regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'SCT with malignant elements'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SCT with malignant elements, locally advanced or metastatic</strong> – For patients with locally advanced or metastatic malignant SCTs, we suggest neoadjuvant platinum-based chemotherapy (prior to attempted surgical resection), rather than adjuvant chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment surveillance</strong> – Children require regular clinical, laboratory, and imaging follow-up after surgical resection or completion of chemotherapy. Follow-up should continue for at least three to five years, as late recurrences have been reported. (See <a class="local">'Surveillance and relapse'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Audet IM, Goldhahn RT Jr, Dent TL. Adult sacrococcygeal teratomas. Am Surg 2000; 66:61.</a></li><li><a class="nounderline abstract_t">Ng EW, Porcu P, Loehrer PJ Sr. Sacrococcygeal teratoma in adults: case reports and a review of the literature. Cancer 1999; 86:1198.</a></li><li><a class="nounderline abstract_t">Swamy R, Embleton N, Hale J. Sacrococcygeal teratoma over two decades: birth prevalence, prenatal diagnosis and clinical outcomes. Prenat Diagn 2008; 28:1048.</a></li><li><a class="nounderline abstract_t">Rescorla FJ, Sawin RS, Coran AG, et al. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group. J Pediatr Surg 1998; 33:171.</a></li><li><a class="nounderline abstract_t">Schropp KP, Lobe TE, Rao B, et al. Sacrococcygeal teratoma: the experience of four decades. J Pediatr Surg 1992; 27:1075.</a></li><li><a class="nounderline abstract_t">Harms D, Zahn S, Göbel U, Schneider DT. Pathology and molecular biology of teratomas in childhood and adolescence. Klin Padiatr 2006; 218:296.</a></li><li><a class="nounderline abstract_t">Huddart SN, Mann JR, Robinson K, et al. Sacrococcygeal teratomas: the UK Children's Cancer Study Group's experience. I. Neonatal. Pediatr Surg Int 2003; 19:47.</a></li><li><a class="nounderline abstract_t">Mann JR, Gray ES, Thornton C, et al. Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience. J Clin Oncol 2008; 26:3590.</a></li><li><a class="nounderline abstract_t">Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 1999; 17:2137.</a></li><li><a class="nounderline abstract_t">Calaminus G, Schneider DT, Bökkerink JP, et al. Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89. J Clin Oncol 2003; 21:781.</a></li><li><a class="nounderline abstract_t">Wakhlu A, Misra S, Tandon RK, Wakhlu AK. Sacrococcygeal teratoma. Pediatr Surg Int 2002; 18:384.</a></li><li><a class="nounderline abstract_t">Göbel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol 2001; 19:1943.</a></li><li><a class="nounderline abstract_t">Hu J, Schuster AE, Fritsch MK, et al. Deletion mapping of 6q21-26 and frequency of 1p36 deletion in childhood endodermal sinus tumors by microsatellite analysis. Oncogene 2001; 20:8042.</a></li><li><a class="nounderline abstract_t">Veltman I, Veltman J, Janssen I, et al. Identification of recurrent chromosomal aberrations in germ cell tumors of neonates and infants using genomewide array-based comparative genomic hybridization. Genes Chromosomes Cancer 2005; 43:367.</a></li><li><a class="nounderline abstract_t">Ayed A, Tonks AM, Lander A, Kilby MD. A review of pregnancies complicated by congenital sacrococcygeal teratoma in the West Midlands region over an 18-year period: population-based, cohort study. Prenat Diagn 2015; 35:1037.</a></li><li><a class="nounderline abstract_t">Hambraeus M, Arnbjörnsson E, Börjesson A, et al. Sacrococcygeal teratoma: A population-based study of incidence and prenatal prognostic factors. J Pediatr Surg 2016; 51:481.</a></li><li><a class="nounderline abstract_t">Mahour GH. Sacrococcygeal teratomas. CA Cancer J Clin 1988; 38:362.</a></li><li><a class="nounderline abstract_t">Altman RP, Randolph JG, Lilly JR. Sacrococcygeal teratoma: American Academy of Pediatrics Surgical Section Survey-1973. J Pediatr Surg 1974; 9:389.</a></li><li><a class="nounderline abstract_t">Wilson RD, Hedrick H, Flake AW, et al. Sacrococcygeal teratomas: prenatal surveillance, growth and pregnancy outcome. Fetal Diagn Ther 2009; 25:15.</a></li><li><a class="nounderline abstract_t">Batukan C, Ozgun MT, Basbug M. First trimester diagnosis of sacrococcygeal teratoma using two- and three-dimensional ultrasound. J Clin Ultrasound 2011; 39:160.</a></li><li><a class="nounderline abstract_t">Roman AS, Monteagudo A, Timor-Tritsch I, Rebarber A. First-trimester diagnosis of sacrococcygeal teratoma: the role of three-dimensional ultrasound. Ultrasound Obstet Gynecol 2004; 23:612.</a></li><li><a class="nounderline abstract_t">Sepulveda W, Wong AE, Fauchon DE. Fetal spinal anomalies in a first-trimester sonographic screening program for aneuploidy. Prenat Diagn 2011; 31:107.</a></li><li><a class="nounderline abstract_t">Danzer E, Hubbard AM, Hedrick HL, et al. Diagnosis and characterization of fetal sacrococcygeal teratoma with prenatal MRI. AJR Am J Roentgenol 2006; 187:W350.</a></li><li><a class="nounderline abstract_t">Kirkinen P, Partanen K, Merikanto J, et al. Ultrasonic and magnetic resonance imaging of fetal sacrococcygeal teratoma. Acta Obstet Gynecol Scand 1997; 76:917.</a></li><li><a class="nounderline abstract_t">Quinn TM, Hubbard AM, Adzick NS. Prenatal magnetic resonance imaging enhances fetal diagnosis. J Pediatr Surg 1998; 33:553.</a></li><li><a class="nounderline abstract_t">Evans MJ, Danielian PJ, Gray ES. Sacrococcygeal teratoma: a case of mistaken identity. Pediatr Radiol 1994; 24:52.</a></li><li><a class="nounderline abstract_t">Sherer DM, Fromberg RA, Rindfusz DW, et al. Color Doppler aided prenatal diagnosis of a type 1 cystic sacrococcygeal teratoma simulating a meningomyelocele. Am J Perinatol 1997; 14:13.</a></li><li><a class="nounderline abstract_t">Yu JA, Sohaey R, Kennedy AM, Selden NR. Terminal myelocystocele and sacrococcygeal teratoma: a comparison of fetal ultrasound presentation and perinatal risk. AJNR Am J Neuroradiol 2007; 28:1058.</a></li><li><a class="nounderline abstract_t">Flake AW. Fetal sacrococcygeal teratoma. Semin Pediatr Surg 1993; 2:113.</a></li><li><a class="nounderline abstract_t">Sy ED, Filly RA, Cheong ML, et al. Prognostic role of tumor-head volume ratio in fetal sacrococcygeal teratoma. Fetal Diagn Ther 2009; 26:75.</a></li><li><a class="nounderline abstract_t">Benachi A, Durin L, Vasseur Maurer S, et al. Prenatally diagnosed sacrococcygeal teratoma: a prognostic classification. J Pediatr Surg 2006; 41:1517.</a></li><li><a class="nounderline abstract_t">Adzick NS. Open fetal surgery for life-threatening fetal anomalies. Semin Fetal Neonatal Med 2010; 15:1.</a></li><li><a class="nounderline abstract_t">Byrne FA, Lee H, Kipps AK, et al. Echocardiographic risk stratification of fetuses with sacrococcygeal teratoma and twin-reversed arterial perfusion. Fetal Diagn Ther 2011; 30:280.</a></li><li><a class="nounderline abstract_t">Rodriguez MA, Cass DL, Lazar DA, et al. Tumor volume to fetal weight ratio as an early prognostic classification for fetal sacrococcygeal teratoma. J Pediatr Surg 2011; 46:1182.</a></li><li><a class="nounderline abstract_t">Shue E, Bolouri M, Jelin EB, et al. Tumor metrics and morphology predict poor prognosis in prenatally diagnosed sacrococcygeal teratoma: a 25-year experience at a single institution. J Pediatr Surg 2013; 48:1225.</a></li><li><a class="nounderline abstract_t">Lee SM, Suh DH, Kim SY, et al. Antenatal Prediction of Neonatal Survival in Sacrococcygeal Teratoma. J Ultrasound Med 2018; 37:2003.</a></li><li><a class="nounderline abstract_t">Akinkuotu AC, Coleman A, Shue E, et al. Predictors of poor prognosis in prenatally diagnosed sacrococcygeal teratoma: A multiinstitutional review. J Pediatr Surg 2015; 50:771.</a></li><li><a class="nounderline abstract_t">van Heurn LJ, Coumans A, Haak MC, et al. Prognostic accuracy of factors associated with poor outcome in prenatally diagnosed sacrococcygeal teratoma: A systematic review and meta-analysis. Prenat Diagn 2023; 43:1495.</a></li><li><a class="nounderline abstract_t">Roybal JL, Moldenhauer JS, Khalek N, et al. Early delivery as an alternative management strategy for selected high-risk fetal sacrococcygeal teratomas. J Pediatr Surg 2011; 46:1325.</a></li><li><a class="nounderline abstract_t">Usui N, Kitano Y, Sago H, et al. Outcomes of prenatally diagnosed sacrococcygeal teratomas: the results of a Japanese nationwide survey. J Pediatr Surg 2012; 47:441.</a></li><li><a class="nounderline abstract_t">Kremer ME, Wellens LM, Derikx JP, et al. Hemorrhage is the most common cause of neonatal mortality in patients with sacrococcygeal teratoma. J Pediatr Surg 2016; 51:1826.</a></li><li><a class="nounderline abstract_t">Makin EC, Hyett J, Ade-Ajayi N, et al. Outcome of antenatally diagnosed sacrococcygeal teratomas: single-center experience (1993-2004). J Pediatr Surg 2006; 41:388.</a></li><li><a class="nounderline abstract_t">Hecher K, Hackelöer BJ. Intrauterine endoscopic laser surgery for fetal sacrococcygeal teratoma. Lancet 1996; 347:470.</a></li><li><a class="nounderline abstract_t">Lam YH, Tang MH, Shek TW. Thermocoagulation of fetal sacrococcygeal teratoma. Prenat Diagn 2002; 22:99.</a></li><li><a class="nounderline abstract_t">Paek BW, Jennings RW, Harrison MR, et al. Radiofrequency ablation of human fetal sacrococcygeal teratoma. Am J Obstet Gynecol 2001; 184:503.</a></li><li><a class="nounderline abstract_t">Jouannic JM, Dommergues M, Auber F, et al. Successful intrauterine shunting of a sacrococcygeal teratoma (SCT) causing fetal bladder obstruction. Prenat Diagn 2001; 21:824.</a></li><li><a class="nounderline abstract_t">Lee MY, Won HS, Hyun MK, et al. Perinatal outcome of sacrococcygeal teratoma. Prenat Diagn 2011; 31:1217.</a></li><li><a class="nounderline abstract_t">Van Mieghem T, Al-Ibrahim A, Deprest J, et al. Minimally invasive therapy for fetal sacrococcygeal teratoma: case series and systematic review of the literature. Ultrasound Obstet Gynecol 2014; 43:611.</a></li><li><a class="nounderline abstract_t">Okada T, Sasaki F, Cho K, et al. Management and outcome in prenatally diagnosed sacrococcygeal teratomas. Pediatr Int 2008; 50:576.</a></li><li><a class="nounderline abstract_t">Wu JT, Book L, Sudar K. Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res 1981; 15:50.</a></li><li><a class="nounderline abstract_t">Barreto MW, Silva LV, Barini R, et al. Alpha-fetoprotein following neonatal resection of sacrococcygeal teratoma. Pediatr Hematol Oncol 2006; 23:287.</a></li><li><a class="nounderline abstract_t">Ein SH, Mancer K, Adeyemi SD. Malignant sacrococcygeal teratoma--endodermal sinus, yolk sac tumor--in infants and children: a 32-year review. J Pediatr Surg 1985; 20:473.</a></li><li><a class="nounderline abstract_t">Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 2006; 24:2544.</a></li><li><a class="nounderline abstract_t">Derikx JP, De Backer A, van de Schoot L, et al. Long-term functional sequelae of sacrococcygeal teratoma: a national study in The Netherlands. J Pediatr Surg 2007; 42:1122.</a></li><li><a class="nounderline abstract_t">Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25:85.</a></li><li><a class="nounderline abstract_t">Partridge EA, Canning D, Long C, et al. Urologic and anorectal complications of sacrococcygeal teratomas: prenatal and postnatal predictors. J Pediatr Surg 2014; 49:139.</a></li><li><a class="nounderline abstract_t">Derikx JP, De Backer A, van de Schoot L, et al. Factors associated with recurrence and metastasis in sacrococcygeal teratoma. Br J Surg 2006; 93:1543.</a></li><li><a class="nounderline abstract_t">Gabra HO, Jesudason EC, McDowell HP, et al. Sacrococcygeal teratoma--a 25-year experience in a UK regional center. J Pediatr Surg 2006; 41:1513.</a></li><li><a class="nounderline abstract_t">Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18:3809.</a></li><li><a class="nounderline abstract_t">Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004; 22:2691.</a></li><li><a class="nounderline abstract_t">Egler RA, Gosiengfiao Y, Russell H, et al. Is surgical resection and observation sufficient for stage I and II sacrococcygeal germ cell tumors? A case series and review. Pediatr Blood Cancer 2017; 64.</a></li><li class="breakAll">Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors. (Protocol summary available on line: http://www.clinicaltrials.gov/ct2/show/NCT00053352?term=agct0132&amp;rank=1, accessed on April 22, 2009).</li><li><a class="nounderline abstract_t">Kops AL, Hulsker CC, Fiocco M, et al. Malignant recurrence after mature Sacrococcygeal teratoma: A meta-analysis and review of the literature. Crit Rev Oncol Hematol 2020; 156:103140.</a></li><li><a class="nounderline abstract_t">Nam SH, Cho MJ, Kim DY, Kim SC. Half-life of alpha-fetoprotein in neonatal sacrococcygeal teratoma. J Pediatr Surg 2018; 53:2470.</a></li><li><a class="nounderline abstract_t">Blohm ME, Vesterling-Hörner D, Calaminus G, Göbel U. Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol 1998; 15:135.</a></li><li><a class="nounderline abstract_t">van Heurn LJ, Knipscheer MM, Derikx JPM, van Heurn LWE. Diagnostic accuracy of serum alpha-fetoprotein levels in diagnosing recurrent sacrococcygeal teratoma: A systematic review. J Pediatr Surg 2020; 55:1732.</a></li><li><a class="nounderline abstract_t">Yao W, Li K, Zheng S, et al. Analysis of recurrence risks for sacrococcygeal teratoma in children. J Pediatr Surg 2014; 49:1839.</a></li><li><a class="nounderline abstract_t">Kondagunta GV, Motzer RJ. Chemotherapy for advanced germ cell tumors. J Clin Oncol 2006; 24:5493.</a></li><li><a class="nounderline abstract_t">Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16:2500.</a></li><li><a class="nounderline abstract_t">Tada T, Takizawa T, Nakazato F, et al. Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue. J Neurooncol 1999; 44:71.</a></li><li><a class="nounderline abstract_t">Margolin KA, Doroshow JH, Frankel P, et al. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biol Blood Marrow Transplant 2005; 11:903.</a></li><li><a class="nounderline abstract_t">Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357:340.</a></li><li><a class="nounderline abstract_t">Pashankar F, Frazier AL, Krailo M, et al. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatr Blood Cancer 2018; 65:e27111.</a></li></ol></div><div id="topicVersionRevision">Topic 5200 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651350" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Adult sacrococcygeal teratomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506704" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sacrococcygeal teratoma in adults: case reports and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973151" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sacrococcygeal teratoma over two decades: birth prevalence, prenatal diagnosis and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498381" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1403540" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sacrococcygeal teratoma: the experience of four decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080330" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pathology and molecular biology of teratomas in childhood and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721723" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sacrococcygeal teratomas: the UK Children's Cancer Study Group's experience. I. Neonatal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541896" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561269" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610174" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12415361" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283126" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753688" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Deletion mapping of 6q21-26 and frequency of 1p36 deletion in childhood endodermal sinus tumors by microsatellite analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15880464" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Identification of recurrent chromosomal aberrations in germ cell tumors of neonates and infants using genomewide array-based comparative genomic hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26114890" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A review of pregnancies complicated by congenital sacrococcygeal teratoma in the West Midlands region over an 18-year period: population-based, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454470" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sacrococcygeal teratoma: A population-based study of incidence and prenatal prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3141009" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sacrococcygeal teratomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4843993" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sacrococcygeal teratoma: American Academy of Pediatrics Surgical Section Survey-1973.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19122459" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sacrococcygeal teratomas: prenatal surveillance, growth and pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21387328" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : First trimester diagnosis of sacrococcygeal teratoma using two- and three-dimensional ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15170807" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : First-trimester diagnosis of sacrococcygeal teratoma: the role of three-dimensional ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20734349" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fetal spinal anomalies in a first-trimester sonographic screening program for aneuploidy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985105" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnosis and characterization of fetal sacrococcygeal teratoma with prenatal MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435729" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ultrasonic and magnetic resonance imaging of fetal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9574750" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prenatal magnetic resonance imaging enhances fetal diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8008498" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sacrococcygeal teratoma: a case of mistaken identity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9259890" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Color Doppler aided prenatal diagnosis of a type 1 cystic sacrococcygeal teratoma simulating a meningomyelocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569957" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Terminal myelocystocele and sacrococcygeal teratoma: a comparison of fetal ultrasound presentation and perinatal risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8062028" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fetal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752518" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prognostic role of tumor-head volume ratio in fetal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16952584" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prenatally diagnosed sacrococcygeal teratoma: a prognostic classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540178" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Open fetal surgery for life-threatening fetal anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086180" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Echocardiographic risk stratification of fetuses with sacrococcygeal teratoma and twin-reversed arterial perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21683219" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tumor volume to fetal weight ratio as an early prognostic classification for fetal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845611" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tumor metrics and morphology predict poor prognosis in prenatally diagnosed sacrococcygeal teratoma: a 25-year experience at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29399854" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antenatal Prediction of Neonatal Survival in Sacrococcygeal Teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25783370" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Predictors of poor prognosis in prenatally diagnosed sacrococcygeal teratoma: A multiinstitutional review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37964422" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prognostic accuracy of factors associated with poor outcome in prenatally diagnosed sacrococcygeal teratoma: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763829" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Early delivery as an alternative management strategy for selected high-risk fetal sacrococcygeal teratomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424335" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Outcomes of prenatally diagnosed sacrococcygeal teratomas: the results of a Japanese nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27502009" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hemorrhage is the most common cause of neonatal mortality in patients with sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481257" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcome of antenatally diagnosed sacrococcygeal teratomas: single-center experience (1993-2004).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618503" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intrauterine endoscopic laser surgery for fetal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857611" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Thermocoagulation of fetal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228510" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Radiofrequency ablation of human fetal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11746122" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful intrauterine shunting of a sacrococcygeal teratoma (SCT) causing fetal bladder obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22024911" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Perinatal outcome of sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24488859" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Minimally invasive therapy for fetal sacrococcygeal teratoma: case series and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937757" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Management and outcome in prenatally diagnosed sacrococcygeal teratomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6163129" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Serum alpha fetoprotein (AFP) levels in normal infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621769" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Alpha-fetoprotein following neonatal resection of sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3903096" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Malignant sacrococcygeal teratoma--endodermal sinus, yolk sac tumor--in infants and children: a 32-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735707" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560233" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term functional sequelae of sacrococcygeal teratoma: a national study in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17194908" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24439598" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Urologic and anorectal complications of sacrococcygeal teratomas: prenatal and postnatal predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17058315" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Factors associated with recurrence and metastasis in sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16952583" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sacrococcygeal teratoma--a 25-year experience in a UK regional center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078494" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15226336" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27786428" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Is surgical resection and observation sufficient for stage I and II sacrococcygeal germ cell tumors? A case series and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27786428" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Is surgical resection and observation sufficient for stage I and II sacrococcygeal germ cell tumors? A case series and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33142194" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Malignant recurrence after mature Sacrococcygeal teratoma: A meta-analysis and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30249359" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Half-life of alpha-fetoprotein in neonatal sacrococcygeal teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9592840" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32376010" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Diagnostic accuracy of serum alpha-fetoprotein levels in diagnosing recurrent sacrococcygeal teratoma: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25487496" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Analysis of recurrence risks for sacrococcygeal teratoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17158534" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Chemotherapy for advanced germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9667270" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10582672" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275593" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652649" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29697191" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
